Columbia University

Technology Ventures

Call for Pre-Proposals: Pfizer's Centers for Therapeutic Innovation (CTI) for Therapeutic Targets

November 02, 2018
05:00pm

Overview: Pfizer’s Centers for Therapeutic Innovation (CTI) is a unique collaboration approach that partners with leading academic medical centers to rapidly translate novel target opportunities into potential new medicines. All researchers and clinicians whose work meets these criteria are invited to apply. Please submit non-confidential pre-proposals to techventures@columbia.edu by November 2nd, 2018.

CTI Collaborations Include:

  • Funding of project-related research 
  • Hands-on partnering from dedicated Pfizer drug-development experts
  • Collaborated use of Pfizer's science and technologies
  • Financial incentives in the form of milestone and royalty payments from successful programs
  • Flexible publishing rights
  • Involvement with CTI's Foundation alliance partners: Lupus Research Alliance, Alzheimer's Drug Discovery Foundation, Crohn's and Colitis Foundation

Modalities Considered:

  • Large Molecules: antibodies, proteins, fusion proteins, antibody conjugates

Pre-Proposal Submission Process:

  • Submission entails a non-confidential 2-3 page overview (template provided) of the target, mechanism, evidence for disease linkage, and the proposed therapeutic drug.  At a high level, the proposal should suggest how the therapeutic
  • All researchers and clinicians whose work meets these criteria are invited to apply. Non-confidential pre-proposals are to be submitted to techventures@columbia.edu by November 2nd, 2018. 

Therapeutic Areas of Interest for Fall 2018:

Disease Area Focus:

  • Cancer – Select solid tumors, such as Colorectal, Breast, Lung (small cell and non-small cell),Pancreatic, Ovarian
  • Autoimmunity/Inflammation – IBD, NAFLD/NASH, Atopic Dermatology, Psoriasis
  • Metabolic - T2DM, Cachexia
  • Rare - ALS, Huntington’s, Duchene’s  or Becker’s muscular dystrophy, non-malignant haematological disorders

Targets/Pathways Focus: 

  • Immune Activators /Enhancers (e.g., nucleic acid sensing, TLRs, etc.)
  • DNA Damage Recognition & Repair (e.g., replication stress or repair enzymes)
  • Tissue–Resident Immune modulation ( adaptive & innate, TME, organ specific, such as skin or gut)
  • Modulation of tumor cell heterogeneity, senescence, plasticity (including drug resistance)
  • Regulation of epithelial biology (i.e. restoring barrier health/integrity)
  • Modulation of fibrosis pathways  either metabolism/stress-induced, or inflammation-induced (possibly tumor-driven)
  • Regulation of antigen-specific tolerance induction and/or modulation of T regulatory cells
  • Treatments for repeat expansion diseases including Huntington’s disease, ALS/FTD and myotonic dystrophy
  • Interventions to address skeletal and cardiac muscle diseases (including Duchenne or Becker muscular dystrophies)

Pre-proposal Submission Process

Submission entails a non-confidential 2-3 page overview of the target, mechanism, evidence for disease linkage, and the proposed therapeutic drug. At a high level, the pre-proposal should suggest how the therapeutic hypothesis could be tested in the clinic. 

For More Information:

Please contact Nader Halim at nader.halim@pfizer.com or Columbia Technology Ventures at techventures@columbia.edu